Merck makes it official: excess bleeding doomed trial
January 20 2011
Merck confirmed that excess bleeding was the reason one of two big clinical trials of experimental blood-thinning agent vorapaxar was ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.